If you look at the Amarin share price last year, the bottom was on July 31...just a few weeks before the stock went sky high on Sept 24.  

It is quite possible that we will follow a similar path.  For Amarin, the skepticism was quite a lot (I was not invested in it, so I am reading up on Vascepa)...no fish oil had succeeded till then, so markets were in a show me mood.

I think that is exactly the attitude towards RVX.  It is a post hoc analysis...Phase 2 blew up spectacularly...it is not proven science...company is out of cash...no institutional investors...these are the usual reasons for avoiding RVX.

But for anyone who has looked at the data so far, it is not a question of whether it will succeed...it is mostly a question of "By how much?"  Are we looking at 30% RRR or even higher? How much will eGFR improve?  MoCA?  Etc.